Correct Answer: C. Rivaroxaban
Rivaroxaban is a direct oral factor Xa inhibitor (DOAC) that selectively inhibits factor Xa in both the intrinsic and extrinsic coagulation pathways, blocking the conversion of prothrombin to thrombin. Unlike parenteral anticoagulants, it has excellent oral bioavailability (~80%) and a predictable pharmacokinetic profile, eliminating the need for monitoring or dose adjustment in most patients. In Indian clinical practice, rivaroxaban is approved for stroke prevention in non-valvular atrial fibrillation (NVAF), treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and thromboprophylaxis after hip/knee replacement surgery. The key discriminating feature is that it is oral (not parenteral) and factor Xa-selective (not thrombin-directed). Its onset is rapid (peak levels in 2–4 hours), and it has a half-life of 5–13 hours, allowing once-daily dosing in most indications. Rivaroxaban does not require INR monitoring, making it superior to warfarin in terms of patient convenience and compliance—a critical advantage in Indian healthcare settings where INR monitoring infrastructure may be limited in peripheral areas.
Why the other options are wrong
A. Bivalirudin — Bivalirudin is a direct thrombin inhibitor (DTI), not a factor Xa inhibitor. It is a synthetic peptide that binds directly to thrombin and is administered intravenously only, making it unsuitable for oral anticoagulation. It is used in acute coronary syndromes and during percutaneous coronary intervention (PCI) in India, but it is parenteral, not oral. B. Enoxaparin — Enoxaparin is a low-molecular-weight heparin (LMWH) that inhibits both factor Xa and thrombin, but it is administered subcutaneously, not orally. While it is widely used in Indian hospitals for DVT/PE prophylaxis and treatment, it is a parenteral anticoagulant and cannot be given by mouth. D. Dabigatran — Dabigatran is an oral direct thrombin inhibitor (DTI), not a factor Xa inhibitor. Although it is an oral DOAC approved in India for NVAF and VTE treatment, it selectively inhibits thrombin (factor IIa), not factor Xa. This is the most common trap—students confuse all DOACs as equivalent when they differ fundamentally in their target.
High-Yield Facts
- Rivaroxaban is a selective factor Xa inhibitor (not thrombin-directed like dabigatran).
- Oral bioavailability of rivaroxaban is ~80% with peak levels in 2–4 hours; half-life 5–13 hours allows once-daily dosing.
- DOACs in India: rivaroxaban and dabigatran are approved for NVAF, DVT/PE; apixaban and edoxaban are also available but rivaroxaban is most commonly prescribed.
- No monitoring required for rivaroxaban (unlike warfarin), improving compliance in Indian outpatient settings.
- Parenteral anticoagulants (enoxaparin, bivalirudin) cannot be given orally; heparins inhibit both Xa and thrombin.
Mnemonics
DOAC Targets Xa inhibitors: Rivaroxaban, Apixaban, Edoxaban (RAE). Thrombin inhibitors: Dabigatran (D). Remember: Rivaroxaban = Xa, Dabigatran = Thrombin. Oral vs Parenteral Oral: DOACs (rivaroxaban, dabigatran, apixaban, edoxaban). Parenteral: Heparins (enoxaparin, LMWH), bivalirudin, fondaparinux. When asked 'oral anticoagulant,' think DOAC first.
NBE Trap
NBE pairs dabigatran (also an oral DOAC) with rivaroxaban to trap students who know DOACs exist but confuse their mechanism—dabigatran targets thrombin (factor IIa), not factor Xa. The question specifically asks for factor Xa inhibitor, making mechanism the discriminator.
Clinical Pearl
In Indian practice, rivaroxaban is preferred over warfarin for NVAF in urban centers because it eliminates the need for INR monitoring—a major advantage when patients live far from pathology labs. However, in resource-limited settings, warfarin remains common due to cost; rivaroxaban is ~10–15 times more expensive, limiting access in government hospitals.
_Reference: KD Tripathi Pharmacology Ch. 45 (Anticoagulants); Harrison Ch. 139 (Antithrombotic Therapy)_